Man turns $20 into $2M after purchasing scratch-off ticket at Shorewood gas station
A man is celebrating after winning $2 million after purchasing a scratch-off ticket at a gas station in Shorewood, Illinois.
The player, nicknamed "Classic Car Collector," purchased a $20 Mega Bucks ticket at Lenny's Gas N Wash at 1201 W. Jefferson Street. Shorewood is a suburb about 45 miles southwest of Chicago.
The player said he was on his way to work when he stopped at the gas station to buy coffee and decided to buy the ticket at the checkout counter. The ticket's purple color displayed on the screen, and he decided to buy it.
He was in shock after scratching the ticket inside his car.
"As more and more zeroes started to appear, and then the final $2,000,000, I just couldn't believe it. I kept staring at the ticket, thinking, there's no way… this can't be real," he said. "I went back into the store and scanned the ticket just to be sure."
The player said even his wife didn't believe him at first.
"My first thought was, 'I've got to get home and tell my wife!' But when I did, she looked at me like I was nuts! I kept saying, 'I just won two million dollars!' and at one point I thought she was going to faint."
Lottery officials said the player won the top prize on the new game launched on April 1.
What does he plan to do with his winnings?
"Collecting classic cars has been a longtime hobby of mine – I've been fortunate enough to own a few over the years. I like working on them, but even more, I love driving them. With this win, I'd like to buy a few acres of land, add another beauty to my collection, and store it there for whenever I want to take a joyride," he said.
The gas station will receive a bonus of $20,000 for selling the ticket. In December 2023, the station also sold a Mega Millions ticket worth $2 million.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 hours ago
- Yahoo
Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the ESMO Gynaecological Cancers Congress 2025
SAN JOSE, Calif., June 9, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Robert Wenham, Chair of the Gynecologic Oncology Program at Moffitt Cancer Center, and the principal investigator of the Phase 1 clinical trial of Anixa's ovarian cancer CAR-T immunotherapy, will present an e-poster at the European Society for Medical Oncology ("ESMO") Gynaecological Cancers Congress 2025, to be held on June 19-21, 2025 in Vienna, Austria. Presentation Details: Title: Phase 1 clinical trial of autologous T-cells genetically engineered with a chimeric receptor to target the follicle stimulating hormone receptor (FSHR) in recurrent ovarian cancer (OVCA) Session Type: E-Poster Poster No.: 145eTiP About Anixa Biosciences, Inc. Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit or follow Anixa on Twitter, LinkedIn, Facebook and YouTube. Forward-Looking StatementsStatements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release. Contact:Mike CatelaniPresident, COO & CFOmcatelani@ View original content to download multimedia: SOURCE Anixa Biosciences, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
1 Cash-Burning Stock to Consider Right Now and 2 to Approach with Caution
Rapid spending isn't always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them vulnerable. Just because a company is spending heavily doesn't mean it's on the right track, and StockStory is here to separate the winners from the losers. That said, here is one high-risk, high-reward company with the potential to scale into a market leader and two that could run into serious trouble. Trailing 12-Month Free Cash Flow Margin: -2.1% Appropriately headquartered in Clearwater, Florida, MarineMax (NYSE:HZO) sells boats, yachts, and other marine products. Why Do We Think Twice About HZO? Store closures and poor same-store sales reveal weak demand and a push toward operational efficiency Lagging same-store sales over the past two years suggest it might have to change its pricing and marketing strategy to stimulate demand Depletion of cash reserves could lead to a fundraising event that triggers shareholder dilution MarineMax is trading at $22.46 per share, or 8.6x forward P/E. Read our free research report to see why you should think twice about including HZO in your portfolio, it's free. Trailing 12-Month Free Cash Flow Margin: -11% The parent company of brands such as Zipcar and Budget Truck Rental, Avis (NASDAQ:CAR) is a provider of car rental and mobility solutions. Why Do We Avoid CAR? Number of available rental days - car rental has disappointed over the past two years, indicating weak demand for its offerings Shrinking returns on capital suggest that increasing competition is eating into the company's profitability Unfavorable liquidity position could lead to additional equity financing that dilutes shareholders Avis Budget Group's stock price of $123.48 implies a valuation ratio of 3.8x forward EV-to-EBITDA. Dive into our free research report to see why there are better opportunities than CAR. Trailing 12-Month Free Cash Flow Margin: -27.5% Founded by an employee at a real estate rental company, SmartRent (NYSE:SMRT) provides smart home devices and software for multifamily residential properties, single-family rental homes, and student housing communities. Why Does SMRT Stand Out? ARR growth averaged 28.5% over the past two years, showing customers are willing to take multi-year bets on its offerings Earnings per share grew by 43% annually over the last two years and trumped its peers At $0.92 per share, SmartRent trades at 1.1x forward price-to-sales. Is now a good time to buy? Find out in our full research report, it's free. Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today for free. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Yahoo
Ohio winner claims $112 million Mega Millions jackpot in trust
CLEVELAND, Ohio (WCMH) — The lucky Ohioan who was the first Mega Millions jackpot winner under the game's new rules has claimed the multi-million dollar prize. The Ohio Lottery announced in a news release that the money won in the April 18, 2025, drawing has been placed in The Ironwood Family Trust, for which James S. Ausse, Esq., is named trustee. The winner had 180 days, or until Oct. 15, 2025, to claim the prize. The ticket, worth $112 million, was purchased at Giant Eagle, 4401 Mayfield Road in South Euclid. According to the lottery, the winner chose their own numbers, which were — 5-13-15-17-28, with the Mega Ball 1. Instead of the 30-year annuity, the winner selected the cash option of $49.3 million. A total of $35.5 million will be placed in the trust after mandatory state and federal taxes of 28%. The overhauled Mega Millions game began on April 5, with the promise of bigger jackpots, better odds and a built-in multiplier that does not cost the player extra money and improves every non-jackpot win by 2X, 3X, 4X, 5X, or 10X. The ticket price was raised from $2 to $5 per wager, however, the game was designed to have no break-even prizes, with all winning tickets totaling $10 or more. Additionally, its jackpots start at $50 million. Since joining Mega Millions, Ohio has had 21 Mega Millions jackpot winners and 65 second-tier winners of $1 million or more. The nationwide game is sold in 45 states, Washington, D.C., and the U.S. Virgin Islands. Drawings are conducted at 11 p.m. Eastern on Tuesdays and Fridays in Atlanta. The next Mega Millions drawing is Friday, June 6, at 11 p.m. The jackpot amount is currently at $223 million. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
